Humana Shares Jump 11% After CMS Sets 2.48% Medicare Advantage Rate
CMS finalized a 2.48% boost to 2027 Medicare Advantage payments, up from a 0.09% preliminary proposal, unlocking an extra $13 billion in federal reimbursements. Humana shares surged 11% on the news, driven by expectations of improved margin recovery and a clearer revenue outlook for its Medicare Advantage business.
1. CMS Finalizes 2.48% Rate for Medicare Advantage
The Centers for Medicare & Medicaid Services finalized a 2.48% increase to Medicare Advantage plan payments for 2027, a substantial rise from the 0.09% provisional rate announced earlier in the year. This adjustment represents the largest MA rate boost since last year's 5.06% increase and reverses expectations of a near-flat reimbursement.
2. Humana Shares Surge on Rate News
Humana shares jumped 11% in response, reaching their highest levels since late March as investors priced in the improved reimbursement outlook. The stock rally outpaced peers, reflecting Humana’s significant exposure to Medicare Advantage and its ability to leverage higher rates.
3. $13 Billion Funding Boost and Margin Outlook
The 2.48% rate hike translates to roughly $13 billion in additional federal reimbursements for private Medicare Advantage insurers in 2027. Insurers anticipate that this funding increase, combined with normal coding trends, will support a 6%-6.5% effective revenue growth, enhancing margin recovery prospects.
4. Profitability Challenges Persist
Despite the positive revision, projected cost trends for Medicare Part A and B remain near 7%, suggesting insurers may rely on modest benefit adjustments to maintain profitability. Uncertainty around future CMS risk adjustment reforms and coding audits continues to pose execution risks.